PCSK9 Inhibitors for Large-Artery Stroke Recovery
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether a cholesterol-lowering medication called evolocumab (a PCSK9 inhibitor) can help people recover better after a specific type of stroke caused by clogged arteries. The study checks if lowering cholesterol further than usual statins do improves stroke outcomes and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–80 years old
- Recent acute ischemic stroke (within 72 hours) confirmed by imaging and diagnosed as large-artery atherosclerosis type
- Mild-to-moderate stroke severity (NIHSS score 4–20)
- No severe heart, liver, or kidney disease
- LDL cholesterol level of at least 1.8 mmol/L (about 70 mg/dL)
- Never taken a PCSK9 inhibitor before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a cholesterol-lowering drug (called a PCSK9 inhibitor) can help people who had a stroke and a procedure to clear a blocked vessel. It aims to see if the drug reduces the risk of another stroke or improves recovery.
This trial tests whether giving a cholesterol-lowering injection (called a PCSK9 inhibitor) early after a stroke helps improve recovery and lowers cholesterol. It is for people whose stroke is caused by narrowed arteries, not by heart problems.
This trial tests whether quickly starting an aggressive cholesterol-lowering treatment after a stroke improves recovery. It is for people who are about to have a procedure to remove a large blood clot from their brain.
This trial tests a smart computer tool that helps doctors manage your cholesterol treatment with Evolocumab (Repatha). If you have had a recent stroke or mini-stroke and are already taking this medicine, the tool may help you reach your LDL (bad cholesterol) goal faster.
This trial tests whether adding an intensive cholesterol-lowering drug (called a PCSK9 inhibitor) to standard care can reduce the risk of another stroke or heart attack in people who recently had a stroke from narrowed brain or neck arteries. It is a high-dose approach designed to rapidly lower cholesterol and may offer extra protection for those with high Lp(a).
This trial tests whether a cholesterol-lowering medicine (called a PCSK9 inhibitor) can help people who recently had a stroke caused by a narrowed artery in the brain. The goal is to see if it reduces the risk of another stroke or helps recovery.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.